How Semaglutide May Protect the Brain After Stroke by Preventing a Type of Cell Death Called Ferroptosis | Research

The takeaway

Semaglutide protected against ischemic stroke brain damage in rats by inhibiting ferroptosis (iron-dependent cell death) through the FoXO1/GPX4 and DRP1/ACSL4 signaling pathways.

Ferroptosis inhibited via 2 pathways
Semaglutide blocked iron-dependent cell death in stroke-damaged brain tissue by simultaneously modulating the FoXO1/GPX4 and DRP1/ACSL4 signaling cascades

What the researchers found

Using a rat model of ischemic stroke (middle cerebral artery occlusion/reperfusion), semaglutide reduced brain tissue damage and neuronal death. At the molecular level, semaglutide activated GLP-1 receptors to modulate two key pathways:

1. **FoXO1/GPX4 pathway**: Semaglutide regulated the FoXO1 transcription factor and increased GPX4 (a key anti-ferroptosis enzyme), inhibiting autophagy (via reduced Beclin1) and preventing ferroptotic cell death.

2. **DRP1/ACSL4 pathway**: Semaglutide suppressed DRP1-mediated mitochondrial fission (fragmentation), promoted Mfn2-mediated mitochondrial fusion, increased ATP production, and reduced reactive oxygen species (ROS). This improved mitochondrial health and reduced ACSL4-dependent ferroptosis.

Bioinformatics analysis predicted these mechanisms, which were then validated through Western blotting, RT-PCR, immunofluorescence, and ELISA experiments.

Why it matters

Stroke is a leading cause of death and disability worldwide, and treatment options during the critical reperfusion period are extremely limited. If semaglutide — a drug already approved and widely used for diabetes and obesity — also protects the brain during stroke, it could be repurposed for neuroprotection. Understanding the specific mechanism (ferroptosis inhibition via mitochondrial protection) also opens new targets for stroke drug development.

How the study worked

Researchers first used bioinformatics analysis to predict how semaglutide might protect against cerebral ischemia-reperfusion injury. They then validated these predictions using a rat middle cerebral artery occlusion/reperfusion (MCAO/R) model — a standard experimental stroke model. Brain tissue from the ischemic penumbra (the salvageable area around the stroke core) was analyzed using histopathology, Western blotting, RT-PCR, immunofluorescence, and ELISA to measure markers of cell death, autophagy, mitochondrial dynamics, and ferroptosis.

What this study cannot tell us

This is an animal study using an artificially induced stroke model in rats, which may not fully replicate human stroke pathophysiology. The specific semaglutide dose, timing of administration (before, during, or after stroke), and treatment duration were not detailed in the abstract. Bioinformatics predictions, while validated experimentally, rely on existing database annotations that may be incomplete. No behavioral or functional recovery outcomes were reported — only molecular and histological markers.

How to read the evidence

This is a preclinical animal study using a rat stroke model with molecular validation techniques. While it provides detailed mechanistic insight, the findings are far from clinical application and have not been tested in humans.

When this study was published

Published in 2025, this study reflects the cutting edge of research into GLP-1 drug neuroprotection and the growing understanding of ferroptosis as a therapeutic target in stroke.

The bigger picture

This study adds to a rapidly growing body of research suggesting GLP-1 receptor agonists have neuroprotective effects beyond their metabolic actions. Previous studies have shown potential benefits in Alzheimer's disease, Parkinson's disease, and traumatic brain injury. The mechanism identified here — inhibiting ferroptosis by improving mitochondrial dynamics — is particularly noteworthy because ferroptosis has emerged as a major driver of brain damage in stroke, and no drugs currently target this pathway clinically. With millions of people already taking semaglutide, observational studies may soon reveal whether GLP-1 drug users have better stroke outcomes.

Questions still open

Would semaglutide need to be present before a stroke occurs to be protective, or could it be administered as an acute treatment after stroke onset?
Do people already taking semaglutide for diabetes or obesity have better outcomes if they experience a stroke?
Could targeting ferroptosis directly with specific inhibitors provide even stronger neuroprotection than working through the GLP-1 receptor?

Common questions

What is ferroptosis and why does it matter in stroke?

Ferroptosis is a type of cell death driven by iron and the buildup of damaged fats (lipid peroxides) in cell membranes. When blood flow returns after a stroke (reperfusion), a flood of iron and free radicals can trigger ferroptosis in brain cells that survived the initial blockage. Unlike other forms of cell death, ferroptosis can potentially be blocked by specific drugs — making it an attractive target for stroke treatment.

Does this mean semaglutide could be used to treat stroke?

Not yet. This study was done in rats, and the jump from animal stroke models to human treatment is one of the most difficult in medicine — many promising neuroprotective drugs have failed in human trials. However, since millions of people already take semaglutide, researchers can study whether existing users have better stroke outcomes. The mechanistic evidence is compelling, but clinical trials are needed.

Read the original research

Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.

Molecular neurobiology, 62(12), 16168-16188

View on PubMed ↗Publisher’s paper ↗

Citation

Wang, Weihua; Pang, Meng; Zhang, Yifeng; Hou, Shuai; Xia, Yulei; Shi, Youkui; Zhang, Xiaojun; Wang, Yanqiang. (2025). Semaglutide Mitigates Ischemic Brain Injury by Inhibiting Ferroptosis via Modulation of FoXO1 and DRP1 Pathways.. Molecular neurobiology, 62(12), 16168-16188. https://doi.org/10.1007/s12035-025-05253-1